Aligos Therapeutics, Inc.
ALGS
$7.55
-$0.82-9.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.27M | 3.95M | 6.00M | 7.97M | 13.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.27M | 3.95M | 6.00M | 7.97M | 13.79M |
| Cost of Revenue | 68.41M | 70.27M | 76.50M | 75.59M | 71.27M |
| Gross Profit | -65.14M | -66.33M | -70.50M | -67.62M | -57.48M |
| SG&A Expenses | 21.22M | 22.83M | 23.37M | 25.18M | 28.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.62M | 93.10M | 99.86M | 100.77M | 99.32M |
| Operating Income | -86.35M | -89.15M | -93.86M | -92.80M | -85.53M |
| Income Before Tax | -52.91M | -130.88M | -76.68M | -75.52M | -98.81M |
| Income Tax Expenses | 350.00K | 331.00K | 274.00K | 212.00K | 780.00K |
| Earnings from Continuing Operations | -53.26 | -131.21 | -76.95 | -75.74 | -99.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.26M | -131.21M | -76.95M | -75.74M | -99.59M |
| EBIT | -86.35M | -89.15M | -93.86M | -92.80M | -85.53M |
| EBITDA | -85.41M | -88.13M | -92.68M | -91.57M | -84.14M |
| EPS Basic | -10.21 | -20.92 | -13.35 | -20.64 | -32.32 |
| Normalized Basic EPS | -6.35 | -13.04 | -8.23 | -12.79 | -19.83 |
| EPS Diluted | -17.51 | -20.98 | -13.40 | -20.70 | -32.32 |
| Normalized Diluted EPS | -6.46 | -13.04 | -8.23 | -12.79 | -19.83 |
| Average Basic Shares Outstanding | 27.22M | 25.06M | 23.85M | 19.31M | 14.78M |
| Average Diluted Shares Outstanding | 27.53M | 25.07M | 23.85M | 19.32M | 14.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |